|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:imdevimab
|
|
gptkbp:activities
|
neutralizes virus
|
|
gptkbp:approves
|
gptkb:drug
November 2020
|
|
gptkbp:can_be_used_with
|
gptkb:etesevimab
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:United_States
gptkb:Eli_Lilly_and_Company
gptkb:Native_American_tribe
gptkb:Research_Institute
combination therapy
Phase 2
monotherapy
|
|
gptkbp:collaborations
|
government agencies
academic institutions
pharmaceutical companies
|
|
gptkbp:developed_by
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:duration
|
single dose
|
|
gptkbp:emergency_services
|
gptkb:FDA
|
|
gptkbp:healthcare
|
improved patient outcomes
contributed to pandemic response
reduced burden on healthcare system
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
bamlanivimab
|
|
gptkbp:indication
|
mild to moderate COVID-19
|
|
gptkbp:invention
|
gptkb:Eli_Lilly_and_Company
patented
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:market
|
adverse event reporting
ongoing monitoring
safety studies
effectiveness studies
available under EUA
|
|
gptkbp:marketed_as
|
gptkb:Bamlanivimab
|
|
gptkbp:operational_status
|
limited supply
|
|
gptkbp:pharmacokinetics
|
half-life of approximately 20 days
|
|
gptkbp:population
|
high-risk patients
|
|
gptkbp:provides_information_on
|
gptkb:hospital
WHO recommendations
outpatient
CDC recommendations
|
|
gptkbp:receives_funding_from
|
public and private funding
|
|
gptkbp:regulatory_compliance
|
Emergency Use Authorization
|
|
gptkbp:research
|
improved recovery time
reduced hospitalization
decreased viral load
reduced emergency visits
|
|
gptkbp:research_focus
|
COVID-19 variants
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
diarrhea
infusion reactions
|
|
gptkbp:social_structure
|
gptkb:Ig_G1
|
|
gptkbp:supply_chain
|
limited availability
|
|
gptkbp:targets
|
gptkb:SARS-Co_V-2
|